Group 1 - The company has started selling its ergotamine series products through various platforms including WeChat Mini Program, Tmall, and JD.com [1] - The company has developed a corresponding plan for the development of the health sector and is currently making steady progress [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Summary of Sichuan Kelun Pharmaceutical FY Conference Company Overview - **Company Name**: Kelun-Biotech - **Industry**: Biopharmaceuticals - **Focus Areas**: Oncology, immunology, metabolism, and other therapeutic areas - **Shareholders**: Kelun Pharmaceutical (largest), MSD (second largest and major collaborator) [2][3] Pipeline and Product Development - **Pipeline Programs**: Over 30 programs, including: - 4 approved products with 7 indications - 2 products at NDA stage - Over 10 programs in clinical development - **Employee Count**: Approximately 2,000, with 900 in R&D, 500 in manufacturing and quality control, and 500 in sales and marketing [3][4] - **Key Products**: - TROP2 ADC (sac-TMT): Approved for three indications in China, including lung cancer and breast cancer - HER2-ADC (trastuzumab botidotec): Approved for HER2-positive breast cancer - Cetuximab: Approved for RAS wild-type colorectal cancer - PD-L1 for nasopharyngeal carcinoma (NPC) [4][5][11] Clinical Studies and Approvals - **Clinical Studies**: Initiated five pivotal studies for breast cancer, six for lung cancer, and one for gastrointestinal cancer [5] - **Expected Approvals**: Anticipation of more product approvals and label expansions in 2026, including a small molecule RET inhibitor [3][6] - **Global Studies**: MSD is initiating 16 global phase three studies for various cancers [9] Market Position and Strategy - **National Reimbursement Drug List (NRDL)**: Three core products included in NRDL 2025, effective January 2026 [7] - **Commercialization Strategy**: Full-fledged commercialization team established with access to Class III hospitals and key opinion leaders [6] - **Partnerships**: Collaborations with MSD, Ellipses, Wonderworld Bio, and Keratin Bio to enhance pipeline value and global market reach [7][8] Innovation and Future Plans - **OptiDC Platform**: Focus on optimized drug conjugate technology, with plans to expand into non-oncology areas [12][15] - **Research Focus**: Development of novel payloads, linkers, and ADC designs, including bispecific antibodies and non-toxin-based drug conjugates [14][15] - **Growth Plans**: Prioritizing differentiated pipeline programs, expanding drug development and commercialization capabilities, and enhancing global partnerships [15][16] Key Performance Metrics - **Efficacy Data**: - TROP2 ADC demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in clinical trials [10] - HER2-ADC showed improved PFS and overall response rate (ORR) compared to T-DM1 [11] This summary encapsulates the key points from the conference, highlighting the company's strategic focus, product pipeline, clinical advancements, and future growth plans.

Core Insights - The social security fund, known as the "national team," has faced significant losses on recent investments in various companies, including Zhongchong Co. and Poly Developments, despite their strong market positions and low price-to-book ratios [1][3][5] - A trend has emerged where the social security fund's investments in leading companies across multiple sectors have resulted in substantial unrealized losses, with many stocks down over 50% over three years [3][5] - The fund's strategy appears to focus on acquiring shares in industry leaders at low valuations, reminiscent of its approach during market downturns in 2018 [5][6] Investment Performance - The social security fund's recent investments include 1.44 million shares of Zhongchong Co., which has a 9% market share in the domestic pet food market, but the stock price has declined since the purchase [1] - Poly Developments, the 2024 real estate sales champion, has a price-to-book ratio of 0.47, yet its stock continues to hit new lows [3] - The fund's investment in China Metallurgical Group resulted in a short-term loss exceeding 80 million yuan after acquiring 100 million shares [3] Sector Analysis - In the aluminum sector, the fund increased its holdings in Nanshan Aluminum to 164 million shares, making it the fifth-largest shareholder, but the stock price has also fallen [3] - The renewable energy sector saw the fund invest in Jiazhe New Energy with 19.45 million shares, despite the company's high gross margin of 57.6% [3] - In the pharmaceutical industry, the fund acquired 13.94 million shares of Kelun Pharmaceutical, which has a market share of over 40% in large-volume parenterals, but the stock price has not improved [5] Long-term Strategy - The social security fund's investment approach reflects a preference for industry leaders, with recent acquisitions spanning real estate, agriculture, mining, and high-end manufacturing [5][6] - The fund's investments are based on thorough research, targeting companies with strong fundamentals that have not yet been fully reflected in their stock prices [11] - The fund's long-term investment horizon is evident, as it continues to invest in companies despite short-term market fluctuations [6][8] Market Trends - The fund's investments align with broader industry trends, such as the focus on food security and the demand for intelligent automotive technologies [6] - The global demand in certain sectors has decreased by 10%, while companies are increasing R&D investments, which may impact short-term profitability but enhance long-term efficiency [8] - Policy changes are affecting valuation systems, with state-owned enterprises being urged to focus on core responsibilities, leading to asset divestitures that may impact market perceptions [9]

Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw materials industry, indicating a steady increase in production and market dynamics from 2025 to 2032 [1] Industry Summary - In November 2025, China's chemical pharmaceutical raw material production reached 331,000 tons, reflecting a year-on-year growth of 1.5% [1] - From January to November 2025, the cumulative production of chemical pharmaceutical raw materials in China was 3,358,000 tons, with a cumulative growth of 1.8% [1] - The report by Zhiyan Consulting provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China, projecting future trends from 2026 to 2032 [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1]

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical and biotechnology sector, with a focus on AI-enabled strategic upgrades in pharmaceutical manufacturing [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a 5.6% increase from December 29, 2025, to January 9, 2026, outperforming the Wind All A index (4.76%) and the CSI 300 index (2.18%). Key segments leading this growth include hospitals (12.95%), medical research outsourcing (9.25%), and medical devices (7.96%) [2][7]. - The report highlights the rapid development of AI in healthcare, emphasizing the government's initiative to foster AI in drug development, supply chain management, surgical robotics, and intelligent diagnostic systems by 2027. This initiative aims to cultivate 2-3 leading ecological enterprises and a number of specialized companies [2][11]. - The upcoming JPM Healthcare Conference from January 12 to 15, 2026, is expected to boost the sentiment in the innovative drug sector, with over 500 listed companies and thousands of startups participating [2][11]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 5.6% during the last interval, with hospitals, medical research outsourcing, and medical devices leading the gains. Notably, the stock of Sanbo Brain Science surged by 63.53%, while *ST Changyao saw a decline of 44.9% [7][10]. - The report provides detailed performance metrics for various sub-sectors, with hospitals showing a 12.95% increase, medical research outsourcing at 9.25%, and medical devices at 7.96% [8][9]. Industry News and Key Company Announcements - On January 7, eight departments jointly issued the "AI + Manufacturing" action plan, marking AI drug development and medical supply chain intelligence as national priorities [11]. - Notable company announcements include: - Yilian Bio's exclusive licensing agreement with Roche for the YL201 project, which includes a $570 million upfront payment [11]. - Merck's discussions to acquire Revolution Medicines for $28 billion to $32 billion [11]. - Structure Therapeutics' agreement with Roche and Genentech for a non-exclusive patent license, resulting in a $100 million upfront payment [11][12]. - Eli Lilly's acquisition of Ventyx Biosciences for $1.2 billion [14].

Core Viewpoint - The Shandong Provincial Drug Administration has imposed an administrative penalty on Chanshin Pharmaceutical Co., Ltd. for producing and selling sodium bicarbonate injection that does not meet national drug standards, resulting in a total fine of 3,125,018.20 yuan [1] Group 1: Regulatory Actions - Chanshin Pharmaceutical was fined 3,031,700 yuan and had 30,464 bottles of the non-compliant sodium bicarbonate injection confiscated due to violations of the Drug Administration Law [1] - The company was found to have produced a batch of sodium bicarbonate injection that failed to meet the required standards, specifically regarding visible foreign substances, and was included in a list of 28 batches of non-compliant drugs [1] Group 2: Company Overview - Chanshin Pharmaceutical, established in 1970 and listed on the Shanghai Stock Exchange in September 2017, is a large comprehensive pharmaceutical company located in Jining, Shandong Province [3] - The company operates five industrial parks covering nearly 2,000 acres, employs over 3,000 people, including more than 1,000 technical professionals, and has total assets of 7.5 billion yuan [3] - Chanshin Pharmaceutical offers over 400 specifications of various drug forms, including large-volume injections, small-volume injections, and raw materials, with a sales network spanning across China and over 50 countries and regions [3]

Group 1 - The core viewpoint of the news is that Kelun Pharmaceutical has experienced a continuous increase in stock price, rising for seven consecutive days with a cumulative increase of 17.86% [1] - As of the report, Kelun Pharmaceutical's stock price is 33.98 yuan per share, with a total market capitalization of 54.302 billion yuan and a trading volume of 876 million yuan [1] - The company's main business involves the development, production, and sales of large-volume infusion products, with revenue composition being 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Shenwan Hongyuan has a significant position in Kelun Pharmaceutical, with a holding of 106,000 shares, representing 1.56% of the fund's net value [2] - The fund, Shenwan Hongyuan CSI Pharmaceutical Bio Index A, has seen a floating profit of approximately 54,620 yuan during the seven-day stock price increase [2] - The fund has a total asset size of 2.22 billion yuan, with a year-to-date return of 6.59% and a one-year return of 20.61% [2]

Investment Rating - The report maintains a positive outlook on innovative drugs and the related industry chain, indicating potential value revaluation for specific pharmaceutical companies [6][28]. Core Insights - The pharmaceutical sector in A-shares showed strong performance in the second week of January 2026, with the SW Pharma Bio index rising by 7.8%, outperforming the overall market [8][29]. - Key sub-sectors such as medical services (+12.3%), medical equipment (+9.4%), and chemical preparations (+7.3%) demonstrated significant growth during this period [13][29]. - Notable individual stock performances included Innovative Medical Management (+61.0%), Sanbo Hospital Management Group (+56.2%), and MeHow Medical (+56.1%) [15][29]. - The report highlights a normal premium level of 68.3% for the pharmaceutical sector relative to all A-shares as of January 9, 2026 [15][23]. Summary by Sections 1. Continued Focus on Innovative Drugs and Industry Chain - The report emphasizes the high prosperity in innovative drugs and suggests monitoring companies like Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical for potential value revaluation [6][28]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of January 2026, the A-share pharmaceutical sector outperformed the market, with the SW Pharma Bio index increasing by 7.8% [8][29]. - The report ranks the pharmaceutical sector as the 5th best-performing industry among Shenwan's primary industries during this period [11][29]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector outperformed the market, with the Hang Seng Healthcare index rising by 10.3% and the biotechnology sector increasing by 11.1% [20][29]. - Conversely, the U.S. pharmaceutical sector underperformed, with the S&P Healthcare Select Sector rising by only 1.1% compared to the S&P 500's 1.6% increase [20][29].

Group 1 - Several funds have shown significant deviations between actual net asset values and estimated net asset values, indicating substantial changes in holdings since the fourth quarter of 2025 [1] - For instance, the GF Vision Smart Selection Mixed Fund saw a net value increase of 4.83% on January 7, 2026, despite most of its top ten holdings declining in value [1] - Similarly, the Huatai-PineBridge Competitive Advantage Mixed Fund experienced a 7.2% increase in net value on the same day, with seven of its top ten holdings also declining [1] Group 2 - New funds are actively entering the market, as evidenced by the Huaan Emerging Power Mixed Fund, which increased by 4.25% on January 7, 2026, suggesting a high stock position likely focused on the technology sector [2] - Institutional holdings have shifted, with notable reductions in positions in companies like Proya and Kelong Pharmaceutical, while new funds have emerged as significant shareholders [3][4] Group 3 - Institutions are increasing their research efforts, with over 11,000 institutional visits recorded in the past month, particularly focusing on advanced manufacturing sectors such as automotive, semiconductors, and general equipment [5][6] - Fund managers emphasize the need for deeper understanding of core business developments and competitive advantages within the industry, especially in light of recent market volatility [7]